SCHEMBL5415300

SCHEMBL5415300

CCNC(=O)Nc1cnc(Nc2ccc(Cl)c(Cl)c2)nc1NC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.46
▸ STK17A Q9UEE5 2/20 0.45
▸ STK17B O94768 1/20 0.45
▸ HDAC3 O15379 1/20 0.45
▸ HDAC1 Q13547 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ HDAC6 Q9UBN7 1/20 0.45
▸ PIK3CA P42336 4/20 0.43
▸ MAPK8 P45983 4/20 0.43
▸ MAPK9 P45984 4/20 0.43
▸ MAPK10 P53779 4/20 0.43
▸ MAPK13 O15264 1/20 0.43
▸ MAPK12 P53778 1/20 0.43
▸ MAPK11 Q15759 1/20 0.43
▸ MAPK14 Q16539 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ JAK2 O60674 2/20 0.42
▸ LRRK2 Q5S007 2/20 0.42
▸ RAB9A P51151 1/20 0.41
▸ ALK Q9UM73 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5408198 0.89 HDAC3 (0.48) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5414078 0.87 HTT (0.47) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5413822 0.87 CYP3A4 (0.53) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5415948 0.85 HDAC3 (0.49) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5416137 0.85 HDAC3 (0.46) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5415421 0.84 STK17A (0.48) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5414041 0.84 STK17A (0.44) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5415230 0.84 EGFR (0.48) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5418427 0.84 HDAC3 (0.47) BRD4STK17ASTK17BHDAC3HDAC1
SCHEMBL5416362 0.83 STK17A (0.46) BRD4STK17ASTK17BHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 BRD4 3015/4885STK17A 3301/4885STK17B 3455/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 BRD4 1419/4885STK17A 3456/4885STK17B 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback